Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer

Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer

Detalhes bibliográficos
Main Authors:	Gillies, R, Delaney, D, Warren, B, Sharma, R, Middleton, MR
Formato:	Conference item
Publicado em:	2011

Registos relacionados

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer
Por: Gillies, R, et al.
Publicado em: (2012)

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.
Por: Gillies, R, et al.
Publicado em: (2012)

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
Por: Hatch, S, et al.
Publicado em: (2014)

Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity
Por: Graf, Nora, et al.
Publicado em: (2012)

Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
Por: MacGregor, T, et al.
Publicado em: (2018)

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
Por: Hatch, S, et al.
Publicado em: (2014)

Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
Por: T. P. MacGregor, et al.
Publicado em: (2018-05-01)

Use of DNA repair proteins translated from biomarker screening to predict overall survival in patients with esophageal cancer treated with oxaliplatin chemotherapy
Por: Sharma, R, et al.
Publicado em: (2012)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
Por: Gillies, R, et al.
Publicado em: (2012)

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma
Por: Gillies, R, et al.
Publicado em: (2012)

XPF-ERCC1: Linchpin of DNA crosslink repair
Por: McHugh, PJ
Publicado em: (2020)

XPF-ERCC1: Linchpin of DNA crosslink repair.
Por: Peter J McHugh
Publicado em: (2020-04-01)

Tissue-Specific DNA Repair Activity of ERCC-1/XPF-1
Por: Mariangela Sabatella, et al.
Publicado em: (2021-01-01)

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.
Por: Findlay, J, et al.
Publicado em: (2017)

Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.
Por: Yang, J, et al.
Publicado em: (2010)

Oesophageal and gastro-oesophageal junction tumours
Por: Bird-Lieberman, E, et al.
Publicado em: (2007)

Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.
Por: Anwaar Ahmad, et al.
Publicado em: (2010-03-01)

Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Por: Findlay, J, et al.
Publicado em: (2017)

Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro‐oesophageal cancer
Por: den Boer, RB, et al.
Publicado em: (2020)

XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
Por: Ming-Yii Huang, et al.
Publicado em: (2023-05-01)

Biochemical studies on the role of the XPF-ERCC1 endonuclease in repairing damaged DNA replication forks
Por: Abdullah, U
Publicado em: (2015)

ERCC1/XPF Is Important for Repair of DNA Double-Strand Breaks Containing Secondary Structures
Por: Shibo Li, et al.
Publicado em: (2019-06-01)

Neoadjuvant chemotherapy for oesophageal carcinoma - a risk factor for postoperative pneumonia?
Por: Millo, J, et al.
Publicado em: (2003)

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
Por: Kaina Bernd, et al.
Publicado em: (2010-09-01)

Optimised oligonucleotide substrates to assay XPF-ERCC1 nuclease activity for the discovery of DNA repair inhibitors
Por: Thomas, A, et al.
Publicado em: (2019)

Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy
Por: Sile Li, et al.
Publicado em: (2022-06-01)

XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair.
Por: Bhagwat, N, et al.
Publicado em: (2009)

Function and Interactions of ERCC1-XPF in DNA Damage Response
Por: Maryam Faridounnia, et al.
Publicado em: (2018-12-01)

Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation
Por: Jiajia Wang, et al.
Publicado em: (2020-02-01)

Human SNM1a and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair
Por: Wang, A, et al.
Publicado em: (2011)

Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair.
Por: Wang, A, et al.
Publicado em: (2011)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
Por: A. G. M. T. Powell, et al.
Publicado em: (2020-08-01)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
Por: Findlay, J, et al.
Publicado em: (2016)

Effect of neoadjuvant chemotherapy on the immune microenvironment of gynaecological tumours
Por: Jing Xue, et al.
Publicado em: (2023-12-01)

Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis
Por: Xin Zhang, et al.
Publicado em: (2021-07-01)

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
Por: Gillies, R, et al.
Publicado em: (2011)

Survival after curative chemoradiotherapy or neoadjuvant therapy and surgery converges in higher-risk patients with oesophageal cancer
Por: Rana, M, et al.
Publicado em: (2021)

A “Inscrição do Harém” de Xerxes (XPf): introdução crítica, tradução de XPf/OP para o português, comparação com XPf/AB e comentários
Por: Matheus Treuk Medeiros de Araújo
Publicado em: (2024-05-01)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
Por: Mukherjee, S, et al.
Publicado em: (2017)

Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer
Por: Gillies, R, et al.
Publicado em: (2010)